Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000252
UniProt IDQ13873
Primary gene name(s)BMPR2
Synonym gene name(s)PPH1
Protein nameBone morphogenetic protein receptor type-2
Protein functionOn ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6. {ECO:0000250|UniProtKB:O35607}.
Subcellular locationCell membrane {ECO:0000269|PubMed:25187962};
Single-pass type I membrane protein.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q13873
Gene Ontology
(Biological Process)
Complete annatation
anterior/posterior pattern specification [GO:0009952];
artery development [GO:0060840];
atrial septum morphogenesis [GO:0060413];
blood vessel remodeling [GO:0001974];
BMP signaling pathway [GO:0030509];
brain development [GO:0007420];
cellular response to BMP stimulus [GO:0071773];
cellular response to starvation [GO:0009267];
chondrocyte development [GO:0002063];
endocardial cushion development [GO:0003197];
endochondral bone morphogenesis [GO:0060350];
endothelial cell apoptotic process [GO:0072577];
endothelial cell proliferation [GO:0001935];
limb development [GO:0060173];
lung alveolus development [GO:0048286];
lymphangiogenesis [GO:0001946];
lymphatic endothelial cell differentiation [GO:0060836];
maternal placenta development [GO:0001893];
mesoderm formation [GO:0001707];
mitral valve morphogenesis [GO:0003183];
negative regulation of cell growth [GO:0030308];
negative regulation of cell proliferation involved in heart valve morphogenesis [GO:0003252];
negative regulation of chondrocyte proliferation [GO:1902731];
negative regulation of DNA biosynthetic process [GO:2000279];
negative regulation of systemic arterial blood pressure [GO:0003085];
negative regulation of vasoconstriction [GO:0045906];
outflow tract morphogenesis [GO:0003151];
outflow tract septum morphogenesis [GO:0003148];
pharyngeal arch artery morphogenesis [GO:0061626];
positive regulation of axon extension involved in axon guidance [GO:0048842];
positive regulation of BMP signaling pathway [GO:0030513];
positive regulation of bone mineralization [GO:0030501];
positive regulation of cartilage development [GO:0061036];
positive regulation of endothelial cell migration [GO:0010595];
positive regulation of endothelial cell proliferation [GO:0001938];
positive regulation of epithelial cell migration [GO:0010634];
positive regulation of ossification [GO:0045778];
positive regulation of osteoblast differentiation [GO:0045669];
positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
proteoglycan biosynthetic process [GO:0030166];
regulation of cell proliferation [GO:0042127];
regulation of lung blood pressure [GO:0014916];
retina vasculature development in camera-type eye [GO:0061298];
semi-lunar valve development [GO:1905314];
transcription from RNA polymerase II promoter [GO:0006366];
transmembrane receptor protein serine/threonine kinase signaling pathway [GO:0007178];
tricuspid valve morphogenesis [GO:0003186];
vascular endothelial growth factor receptor signaling pathway [GO:0048010];
venous blood vessel development [GO:0060841];
ventricular septum morphogenesis [GO:0060412]
Gene Ontology
(Molecular Function)
Complete annatation
activin receptor activity, type II [GO:0016362];
ATP binding [GO:0005524];
BMP binding [GO:0036122];
BMP receptor activity [GO:0098821];
metal ion binding [GO:0046872];
receptor signaling protein serine/threonine kinase activity [GO:0004702]
Gene Ontology
(Cellular Component)
Complete annatation
apical plasma membrane [GO:0016324];
basal plasma membrane [GO:0009925];
caveola [GO:0005901];
cell surface [GO:0009986];
cytoplasm [GO:0005737];
dendrite [GO:0030425];
extracellular space [GO:0005615];
integral component of plasma membrane [GO:0005887];
neuronal cell body [GO:0043025];
neuronal postsynaptic density [GO:0097481];
plasma membrane [GO:0005886];
spanning component of plasma membrane [GO:0044214]
Protein-protein interaction107127
Phylogenetic treeQ13873
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.02600633315686130.9372412187959310.959547681353153
AZA vs. DISU0.2879422921403120.4117011319697390.908954166533642
AZA vs. IL7-0.2767345224344210.2740419451288360.999311006273513
AZA vs. SAHA0.8571009475503920.003865393903614180.0519924781166601
DISU vs. CD30.2492113996206130.5306749488757030.651894236765737
DISU vs. IL7-0.5727674179254110.1056793093480430.427199793530442
DISU vs. SAHA0.5688234777362450.1497744840783550.497082415667231
DMSO vs. AZA-0.1119082297319990.5480190593452871
DMSO vs. CD3-0.1512998120137130.6393925488253360.730239644413259
DMSO vs. DISU-0.4023290434871940.1958218759270380.713270904924328
DMSO vs. IL7-0.1576327113077170.4143367753070470.849620037179095
DMSO vs. SAHA0.9609698403114930.0001182418285938790.00396927973854669
HIV vs. Mock in Activation-0.1671684525097230.7896999829967080.999983755607037
HIV vs. Mock in Latency-0.03023956207076630.8563234463440650.999834320637052
IL7 vs. CD3-0.2927915229163030.3690795460573250.506568566538158
SAHA vs. CD30.8038238519359890.02384860872497390.0533786623325941
SAHA vs. IL71.128413553177520.0002070623245666870.0034254723326146
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change 1.411008177
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.174937 0.234054
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
2HLQ X-ray 1.4Å A=33-131.
3G2F X-ray 2.3Å A/B=189-517.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 downregulates 24008158
Tat modulates 24008158
Tat inhibited by 24008158
Nef downregulates 24008158
Tat downregulates 16282533

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04350 TGF-beta signaling pathway - Homo sapiens (human)
hsa04360 Axon guidance - Homo sapiens (human)
hsa04390 Hippo signaling pathway - Homo sapiens (human)
hsa04550 Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)
hsa05206 MicroRNAs in cancer - Homo sapiens (human)